January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
June 2026 in “British Journal of Dermatology” Ritlecitinib is effective and safe for treating alopecia areata, especially in newer cases.
July 2026 in “Research Square” 28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
Baricitinib is more effective than methotrexate for severe alopecia areata.
January 2023 in “Dermatologic Therapy” The nutritional supplement Pilopeptan® WOMAN improved hair growth and thickness in women with hair loss.
1 citations
,
December 2020 in “Medical lasers” The laser therapy device effectively increased hair growth in people with androgenetic alopecia.
11 citations
,
November 2018 in “British Journal of Dermatology” Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.
1 citations
,
November 2022 in “Journal of the Endocrine Society” Adults with classic congenital adrenal hyperplasia value medication that prevents weight gain from glucocorticoids the most.
1 citations
,
March 2024 in “Skin health and disease” Vibration assisted analgesia reduces pain during corticosteroid therapy for alopecia.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
2 citations
,
May 2016 in “Journal of Clinical Oncology” Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
January 2026 in “American Journal of Translational Research” The metoprolol-spironolactone combination improves heart function in patients with coronary heart disease and heart failure.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
July 2026 in “Journal of the American Academy of Dermatology”
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
January 2025 in “Journal of Bacha Khan Medical College.” Double-spin PRP is more effective for treating male pattern baldness.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
4 citations
,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
2 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The botanical treatment for hair loss shows promise, especially for children.
18 citations
,
April 2021 in “PLOS ONE” The review concluded that reporting on PRP therapy is often incomplete, leading to uncertainty about its effectiveness.
2 citations
,
July 2024 in “Biomedicines” Bone marrow cells improved tendon health better than platelet-rich plasma.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.